πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

4,413 results for β€œACE” Clear

  1. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Infection

    phase 3 small molecule terminated

    1 trial
  2. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 3 mab completed

    1 trial
  3. Pelacarsen

    Novartis Pharmaceuticals

    Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial
  4. Phase 2; Low Dose MYOBLOC

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule active

    1 trial
  5. Phase 2; Low Dose MYOBLOC (15,000 Units)

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule terminated

    1 trial
  6. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Irritability Associated With Autism Spectrum Disorder

    phase 3 small molecule completed

    2 trials
  7. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    phase 3 small molecule completed

    2 trials
  8. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Adjunctive Treatment of Major Depressive Disorder

    phase 3 small molecule terminated

    3 trials
  9. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 3 small molecule completed

    4 trials
  10. Pimavanserin tartrate (ACP-103)

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    4 trials
  11. Pioglitazone, EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE, GLIMEPIRIDE, GLICLAZIDE, METFORMIN HYDROCHLORIDE, GLIPIZIDE, METFORMIN HYDROCHLORIDE, EMPAGLIFLOZIN, GLIQUIDONE, Placebo for Actos 15 mg tablets, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

    Celltrion Healthcare Australia Pty Ltd

    Type 2 diabetes mellitus (T2DM)

    phase 3 small molecule active

    1 trial
  12. Placebo

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials
  13. Placebo

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    3 trials
  14. Placebo

    Novartis Pharmaceuticals

    IC-MPGN

    phase 3 small molecule active

    1 trial
  15. Placebo

    Amneal Pharma Europe Ltd

    Asthma

    phase 3 small molecule active

    1 trial
  16. Placebo

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule completed

    1 trial
  17. Placebo

    Sanofi Pasteur

    Osteoarthritis

    phase 3 small molecule completed

    1 trial
  18. Placebo

    Takeda

    Diabetes

    phase 3 small molecule terminated

    1 trial
  19. Placebo

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial
  20. Placebo

    Hospital Authority, Hong Kong

    Congenital Heart Disease in Children

    phase 3 small molecule completed

    1 trial
  21. Placebo

    Agios Netherlands B.V.

    Pyruvate Kinase Deficiency

    phase 3 small molecule completed

    1 trial
  22. Placebo

    Takeda

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial
  23. Placebo

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial
  24. Placebo

    Tobira Therapeutics

    Nonalcoholic Steatohepatitis

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources